Considerations for the implementation of novel therapies into ALL clinical practice

Robin Foà, MD, Sapienza University of Rome, Rome, Italy, addresses key considerations for integrating novel therapies into clinical practice for acute lymphoblastic leukemia (ALL). He emphasizes early diagnosis of Philadelphia-chromosome positive (Ph+) patients, the importance of tyrosine kinase inhibitors (TKIs) availability, and the significance of measurable residual disease (MRD) analysis using quantitative polymerase chain reaction (PCR). Additionally, Prof. Foà notes the advancements achieved with blinatumomab approval, highlighting ongoing challenges related to access inequality. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.